NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that it has received approval from the New York State Department of Health to market its ThyGenX next-generation sequencing oncogene panel for indeterminate thyroid nodules.

In early August, the company said that its ThyraMir thyroid cancer classifier test had been approved by New York State, and that it planned to submit ThyGenX for approval as well.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.